Trials / Active Not Recruiting
Active Not RecruitingNCT04162015
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable Malignant Pleural Mesothelioma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | nivolumab 360 mg |
| DRUG | Pemetrexed | 500 mg/m\^2 |
| DRUG | Cisplatin or Carboplatin | cisplatin 75 mg/m2 or carboplatin AUC=5 |
Timeline
- Start date
- 2019-11-12
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2019-11-13
- Last updated
- 2025-09-12
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04162015. Inclusion in this directory is not an endorsement.